Market Overview

Insmed Up Over 30% Following FDA Decision

Related INSM
Events Scheduled for Week of Jun 23rd to Jun 27th, 2014
Insmed Soars on Arikayce's Breakthrough Designation - Analyst Blog

Insmed (NASDAQ: INSM) shareholders are having a big day. Shares are up over 33 percent after the company announced that the FDA granted Arikayce breakthrough therapy designation.

Arikayce is designed to treat lung infections; more specifically, nontuberculous mycobacterial lung disease.

Insmed further stated that the designation was based on results from the phase two trial and the company plans to meet with the FDA to form a regulation pathway.

Shares were last trading at $16.65, a 33.57 percent gain.

Posted-In: News FDA


Most Popular

Related Articles (INSM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters